Publications and Presenations
Dr. Vladimir TorchilinSawant RR, Torchilin VP. Challenges in Development of Targeted Liposomal Therapeutics. AAPS J. 2012 Mar 14. [Epub ahead of print]
Zhu L, Kate P, Torchilin VP. Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano. 2012 Mar 14. [Epub ahead of print]
Dao KL, Sawant R, Hendricks JA, Ronga V, Torchilin V, Hanson RN. Design, Synthesis, and Initial Biological Evaluation of a Steroidal Anti-estrogen-Doxorubicin Hybrid for Targeting Estrogen Receptor-Positive Breast Cancer Cells. Bioconjug Chem. 2012 Mar 11. [Epub ahead of print]
Chernenko T, Sawant RR, Miljkovic M, Quintero L, Diem M, Torchilin V. Raman Microscopy for Noninvasive Imaging of Pharmaceutical Nanocarriers: Intracellular Distribution of Cationic Liposomes of Different Composition. Mol Pharm. 2012 Mar 15. [Epub ahead of print]
Sawant RR, Sriraman SK, Navarro G, Biswas S, Dalvi RA, Torchilin VP. Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials. 2012 May;33(15):3942-51. Epub 2012 Feb 25.
Koshkaryev A, Piroyan A, Torchilin VP. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther. 2012 Jan 1;13(1):50-60.
Etzerodt A, Maniecki MB, Graversen JH, Møller HJ, Torchilin VP, Moestrup SK. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release. 2012 Jan 27. [Epub ahead of print]
Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release. 2012 Jan 20. [Epub ahead of print]
Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Torchilin V, Goldberg SN. Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: Reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J Control Release. 2011 Dec 30. [Epub ahead of print]
Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, Torchilin VP. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond). 2012 Jan;7(1):65-78.
Koren E, Apte A, Jani A, Torchilin VP. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release. 2011 Dec 13. [Epub ahead of print]
Miao B, Skidan I, Yang J, You Z, Fu X, Famulok M, Schaffhausen B, Torchilin V, Yuan J, Degterev A. Inhibition of cell migration by PITENINs: the role of ARF6.Oncogene. 2011 Dec 19. doi: 10.1038/onc.2011.593. [Epub ahead of print]
Buyens K, De Smedt SC, Braeckmans K, Demeester J, Peeters L, van Grunsven LA, de Mollerat du Jeu X, Sawant R, Torchilin V, Farkasova K, Ogris M, Sanders NN. Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J Control Release. 2011 Oct 14. [Epub ahead of print]
Movassaghian S, Moghimi HR, Shirazi FH, Torchilin VP. Dendrosome-dendriplex inside liposomes: as a gene delivery system. J Drug Target. 2011 Dec;19(10):925-32. Epub 2011 Oct 24.
Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP. Screening and optimization of ligand conjugates for lysosomal targeting. Bioconjug Chem. 2011 Nov 16;22(11):2271-82. Epub 2011 Oct 6.
Biswas S, Dodwadkar NS, Sawant RR, Torchilin VP. Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug Chem. 2011 Oct 19;22(10):2005-13. Epub 2011 Sep 12.
Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Collins M, Signoretti S, Torchilin V, Goldberg SN. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int J Hyperthermia. 2011;27(6):527-38.
Sawant RR, Vaze OS, Wang T, D'Souza GG, Rockwell K, Gada K, Khaw BA, Torchilin VP. Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration. Pharm Res. 2012 Feb;29(2):375-83. Epub 2011 Aug 16.
Wang T, Upponi JR, Torchilin VP. Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies. Int J Pharm. 2012 May 1;427(1):3-20. Epub 2011 Jul 22.
Meerovich I, Koshkaryev A, Torchilin VP. Kinetic and thermodynamic approaches to the drug targeting phenomena. Curr Drug Discov Technol. 2011 Dec 1;8(4):287-300.
Wang T, Kulkarni N, D'Souza GG, Petrenko VA, Torchilin VP. On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters. Mol Pharm. 2011 Oct 3;8(5):1720-8. Epub 2011 Jul 29.
Dr. Ban-an Khaw
Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Khaw BA. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug-conjugates. EJNMMI DOI 10,1007/s00259-011-2050-3.
Gada KS, Patil V, Panwar R, Majewski S, Khaw BA. In vitro enhanced breast cancer toxicity and decreased cardiocyte toxicity with targeted polymer-drug-conjugates pretargeted with bispecific antibody complexes. Drug Delivery and Translational Research. 2012; 2: 65-76.
Dr. Ralph Loring
University of Florida, Dept. of Pharmacology and Therapeutics in Gainesville Florida "Investigating Novel Nicotinic Receptor Chaperones and Signaling Systems. March, 2012.